Following a SARS-CoV-2 infection, many individuals suffer from post-COVID-19 syndrome. It makes them unable to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints. Several investigators could demonstrate that the SARS-CoV-2 related spike glycoprotein (SGP) attaches not only to ACE-2 receptors but also shows DNA sections highly affine to nicotinic acetylcholine receptors (nAChRs). The nAChR is the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh). We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.
Dr. Ardis stressed in his interview with Rick Rene that if you decide to try this, the lowest dose (7mg/Step 3) patches should be used. More is NOT better!
Sources:
https://doi.org/10.21203/rs.3.rs-2063399/v1.
Research Journal.
https://doi.org/10.1186/s42234-023-00104-7.
Research Journal.
Related:
https://doi.org/10.1016/j.toxrep.2020.04.012.
Research Journal.
https://www.bitchute.com/video/9jEARblbFCea/.
Video.
Dr. Ardis interview begins at 31:05.